1
|
Sharma R, Harrison STL, Tai SL. Advances in Bioreactor Systems for the Production of Biologicals in Mammalian Cells. CHEMBIOENG REVIEWS 2021. [DOI: 10.1002/cben.202100022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Rajesh Sharma
- University of Cape Town Centre for Bioprocess Engineering Research (CeBER) Department of Chemical Engineering Faculty of Engineering and the Built Environment Private Bag 7701 Rondebosch South Africa
| | - Susan T. L. Harrison
- University of Cape Town Centre for Bioprocess Engineering Research (CeBER) Department of Chemical Engineering Faculty of Engineering and the Built Environment Private Bag 7701 Rondebosch South Africa
| | - Siew Leng Tai
- University of Cape Town Centre for Bioprocess Engineering Research (CeBER) Department of Chemical Engineering Faculty of Engineering and the Built Environment Private Bag 7701 Rondebosch South Africa
| |
Collapse
|
2
|
Prat S, Gallardo-Villares S, Vives M, Carreño A, Caminal M, Oliver-Vila I, Chaverri D, Blanco M, Codinach M, Huguet P, Ramírez J, Pinto JA, Aguirre M, Coll R, Garcia-López J, Granell-Escobar F, Vives J. Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis. J Tissue Eng Regen Med 2017; 12:e532-e540. [DOI: 10.1002/term.2323] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Revised: 08/03/2016] [Accepted: 09/26/2016] [Indexed: 12/16/2022]
Affiliation(s)
- Salvi Prat
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Clínic; University of Barcelona; Barcelona Spain
| | - Santiago Gallardo-Villares
- Servicio de Cirugía Ortopédica y Traumatología; Hospital ASEPEYO, Avinguda Alcalde Barnils; Barcelona Spain
| | - Marian Vives
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Clínic; University of Barcelona; Barcelona Spain
| | - Ana Carreño
- Servicio de Cirugía Ortopédica y Traumatología, Hospital Clínic; University of Barcelona; Barcelona Spain
| | - Marta Caminal
- Banc de Sang i Teixits, Edifici Dr Frederic Duran i Jordà; Barcelona Spain
| | - Irene Oliver-Vila
- Banc de Sang i Teixits, Edifici Dr Frederic Duran i Jordà; Barcelona Spain
| | - Daniel Chaverri
- Servicio de Cirugía Ortopédica y Traumatología; Hospital ASEPEYO, Avinguda Alcalde Barnils; Barcelona Spain
| | - Margarita Blanco
- Banc de Sang i Teixits, Edifici Dr Frederic Duran i Jordà; Barcelona Spain
| | - Margarita Codinach
- Banc de Sang i Teixits, Edifici Dr Frederic Duran i Jordà; Barcelona Spain
| | - Pere Huguet
- Servei d'Anatomia Patològica; Hospital Universitari Vall d'Hebron; Barcelona Spain
| | - José Ramírez
- Servicio de Anatomía Patológica, Hospital Clinic; University of Barcelona, Villarroel; Barcelona Spain
| | - Javier A. Pinto
- Servicio de Cirugía Ortopédica y Traumatología; Hospital ASEPEYO, Avinguda Alcalde Barnils; Barcelona Spain
| | - Màrius Aguirre
- Orthopaedic Surgery and Traumatology; Hospital Universitari Vall d'Hebron; Barcelona Spain
| | - Ruth Coll
- Banc de Sang i Teixits, Edifici Dr Frederic Duran i Jordà; Barcelona Spain
| | - Joan Garcia-López
- Banc de Sang i Teixits, Edifici Dr Frederic Duran i Jordà; Barcelona Spain
- Chair of Transfusion Medicine and Cellular and Tissue Therapies; Universitat Autònoma de Barcelona, Campus UAB, Cerdanyola del Vallès; Bellaterra Spain
| | - Fernando Granell-Escobar
- Servicio de Cirugía Ortopédica y Traumatología; Hospital ASEPEYO, Avinguda Alcalde Barnils; Barcelona Spain
| | - Joaquim Vives
- Banc de Sang i Teixits, Edifici Dr Frederic Duran i Jordà; Barcelona Spain
- Departament de Medicina; Universitat Autònoma de Barcelona; Barcelona Spain
| |
Collapse
|
3
|
Caminal M, Vélez R, Rabanal RM, Vivas D, Batlle-Morera L, Aguirre M, Barquinero J, García J, Vives J. A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies. J Tissue Eng Regen Med 2016; 11:3408-3416. [PMID: 27860364 DOI: 10.1002/term.2254] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2015] [Revised: 03/14/2016] [Accepted: 07/03/2016] [Indexed: 01/08/2023]
Abstract
The use of multipotent mesenchymal stromal cells (MSCs) as candidate medicines for treating a variety of pathologies is based on their qualities as either progenitors for the regeneration of damaged tissue or producers of a number of molecules with pharmacological properties. Preclinical product development programmes include the use of well characterized cell populations for proof of efficacy and safety studies before testing in humans. In the field of orthopaedics, an increasing number of translational studies use sheep as an in vivo test system because of the similarities with humans in size and musculoskeletal architecture. However, robust and reproducible methods for the isolation, expansion, manipulation and characterization of ovine MSCs have not yet been standardised. The present study describes a method for isolation and expansion of fibroblastic-like, adherent ovine MSCs that express CD44, CD90, CD140a, CD105 and CD166, and display trilineage differentiation potential. The 3-week bioprocess proposed here typically yielded cell densities of 1.4 × 104 MSCs/cm2 at passage 2, with an expansion factor of 37.8 and approximately eight cumulative population doublings. The osteogenic potential of MSCs derived following this methodology was further evaluated in vivo in a translational model of osteonecrosis of the femoral head, in which the persistence of grafted cells in the host tissue and their lineage commitment into osteoblasts and osteocytes was demonstrated by tracking enhanced green fluorescent protein-labelled cells. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Marta Caminal
- Servei de Teràpia Cel·lular, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain
| | - Roberto Vélez
- Orthopaedic Surgery and Traumatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Rosa Maria Rabanal
- Departament de Medicina i Cirurgia Animals, Àrea de Medicina i Cirurgia Animal, Facultat de Veterinària, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - Daniel Vivas
- Servei de Teràpia Cel·lular, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain
| | | | - Màrius Aguirre
- Orthopaedic Surgery and Traumatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Jordi Barquinero
- Grup de Teràpia Gènica i Cel·lular, Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Joan García
- Servei de Teràpia Cel·lular, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain.,Chair of Transfusion Medicine and Cellular and Tissue Therapies, Universitat Autònoma de Barcelona,Campus UAB, Bellaterra, Spain
| | - Joaquim Vives
- Servei de Teràpia Cel·lular, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain
| |
Collapse
|
4
|
Long Q, Liu X, Yang Y, Li L, Harvey L, McNeil B, Bai Z. The development and application of high throughput cultivation technology in bioprocess development. J Biotechnol 2014; 192 Pt B:323-38. [PMID: 24698846 DOI: 10.1016/j.jbiotec.2014.03.028] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2013] [Revised: 03/18/2014] [Accepted: 03/24/2014] [Indexed: 01/06/2023]
Abstract
This review focuses on recent progress in the technology of high throughput (HTP) cultivation and its increasing application in quality by design (QbD) -driven bioprocess development. Several practical HTP strategies aimed at shortening process development (PD) timelines from DNA to large scale processes involving commercially available HTP technology platforms, including microtiter plate (MTP) culture, micro-scale bioreactors, and in parallel fermentation systems, etc., are critically reviewed in detail. This discussion focuses upon the relative strengths and weaknesses or limitations of each of these platforms in this context. Emerging prototypes of micro-bioreactors reported recently, such as milliliter (mL) scale stirred tank bioreactors, and microfludics integrated micro-scale bioreactors, and their potential for practical application in QbD-driven HTP process development are also critically appraised. The overall aim of such technology is to rapidly gain process insights, and since the analytical technology deployed in HTP systems is critically important to the achievement of this aim, this rapidly developing area is discussed. Finally, general future trends are critically reviewed.
Collapse
Affiliation(s)
- Quan Long
- Jiangnan University, Jiangsu, Wuxi, 214122, PR China
| | - Xiuxia Liu
- Jiangnan University, Jiangsu, Wuxi, 214122, PR China
| | - Yankun Yang
- Jiangnan University, Jiangsu, Wuxi, 214122, PR China
| | - Lu Li
- Jiangnan University, Jiangsu, Wuxi, 214122, PR China
| | | | | | - Zhonghu Bai
- Jiangnan University, Jiangsu, Wuxi, 214122, PR China.
| |
Collapse
|